Table III.

Decreased infections 6 to 12 months compared with 0 to 6 months; 12 to 24 months compared with less than 12 months for FAS

	1-Year Analysis		2-Year Analysis
	Onset Within 6 Months	Onset 6 to ≤12 Months	Onset Within 12 Months	Onset 12 to ≤24 Months
No. of patients analyzed*	N = 72		N = 69
No. of patients with event during the interval	67	38	68	35
Mean (SD) No. of events per patient	3.5 (2.6)	2.3 (2.4)	4.4 (3.6)	2.7 (3.0)
Median (IQR†) No. of events per patient	3.0 (1.0, 5.0)	1.5 (1.0, 3.0)	3.0 (2.0, 6.0)	2.0 (1.0, 3.0)
P value‡	< .001		< .001

To be included in the 1-year analysis, patients must have been alive and on follow-up for at least 365 days after administration of cultured thymus tissue, and experienced at least one infection-related AE during one or both onset periods.

To be included in the 2-year analysis, patients must have been alive and on follow-up for at least 790 days after administration of cultured thymus tissue, and experienced at least one infection-related AE during one or both onset periods.

^*Number of patients who had events during the analysis period.

^†IQR, interquartile range.

^‡2-sided P value based on a Wilcoxon signed-rank test of the mean difference in the number of infection-related AEs per patient between the first and second intervals.